Sacituzumab govitecan (SG) plus enfortumab vedotin (EV) for metastatic urothelial carcinoma (mUC) treatment-experienced (DAD) and with pembrolizumab (P) in treatment naïve UC (DAD-IO)

Category Primary study
JournalJournal of Clinical Oncology
Year 2024
This article has no abstract
Epistemonikos ID: f42c9a12616e0e9bb695c2cf1eef166d5473d5e1
First added on: Feb 18, 2025